Evidence map›Paper›PMID 42121002›Full record

ArticleActa neuropathologica communications2026

Knockout of Rab27b exacerbates neuropathology in alpha-synuclein mouse models.

Kasandra Scholz, Mary A Gannon, Lehmann Matheny, Rohma Syed, William J Stone, Carley Craig, Roschongporn Ekkatine, Talene A Yacoubian

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neuropathologica communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Kasandra ScholzDepartment of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, Civitan International Research Center, University of Alabama at Birmingham, 510A, 1719 6th Avenue South, Birmingham, AL, 35294, USA.
Mary A GannonDepartment of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, Civitan International Research Center, University of Alabama at Birmingham, 510A, 1719 6th Avenue South, Birmingham, AL, 35294, USA.
Lehmann MathenyDepartment of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, Civitan International Research Center, University of Alabama at Birmingham, 510A, 1719 6th Avenue South, Birmingham, AL, 35294, USA.
Rohma SyedDepartment of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, Civitan International Research Center, University of Alabama at Birmingham, 510A, 1719 6th Avenue South, Birmingham, AL, 35294, USA.
William J StoneDepartment of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, Civitan International Research Center, University of Alabama at Birmingham, 510A, 1719 6th Avenue South, Birmingham, AL, 35294, USA.
Carley CraigDepartment of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, Civitan International Research Center, University of Alabama at Birmingham, 510A, 1719 6th Avenue South, Birmingham, AL, 35294, USA.
Roschongporn EkkatineDepartment of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, Civitan International Research Center, University of Alabama at Birmingham, 510A, 1719 6th Avenue South, Birmingham, AL, 35294, USA.
Talene A YacoubianDepartment of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, Civitan International Research Center, University of Alabama at Birmingham, 510A, 1719 6th Avenue South, Birmingham, AL, 35294, USA. tyacoubian@uabmc.edu.

Funding

Project 3: LRRK2 mediated macrophage responses in PDP50NS108675 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI VOLPICELLI-DALEY, LAURA A. · 2018 to 2022
$9.9M
UAB Predoctoral Training Grant in Translational and Molecular SciencesT32GM135028 · NIGMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Mythreye Karthikeyan, RAKESH P. PATEL · 2021 to 2026
$1.6M
UAB Training Program In NeuroscienceT32NS095775 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Erik D Roberson · 2017 to 2026
$1.6M
Role of Rab27b in synucleinopathiesRF1NS115767 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI YACOUBIAN, TALENE ALENE · 2021 to 2021
$1.4M
Role of Rab27 Isoforms on Alpha-Synuclein Endocytosis and ClearanceF31NS135928 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SCHOLZ, KASANDRA J · 2024 to 2025
$81k
NIGMS NIH HHS T32 GM135028NINDS NIH HHS F31 NS135928NINDS NIH HHS P50 NS108675NINDS NIH HHS RF1 NS115767NINDS NIH HHS T32 NS095775
6 · The paper itself

Abstract

Parkinson's Disease (PD) and other synucleinopathies are characterized by the formation of inclusions comprised of alpha-synuclein (αsyn) among other proteins, but the mechanisms by which these inclusions form and cause toxicity are not well understood. We have previously reported that the small GTPase Rab27b modulates autophagic-lysosomal function in neurons and supports lysosomal degradation of αsyn across multiple αsyn cellular models. Knockout (KO) and knockdown (KD) of Rab27b damage lysosomal degradative capacity and exacerbate αsyn pathology, while Rab27b overexpression is conversely protective in cellular αsyn models. Elevations of Rab27b seen in human synucleinopathies suggest a compensatory role for Rab27b in these disorders. Here, we examined the role Rab27b plays in vivo in the context of both A53T genetic αsyn overexpression and viral AAV αsyn overexpression mouse models. Rab27b knockout in A53T

Indexed as

alpha-SynucleinBrainrab GTP-Binding ProteinsSynucleinopathiesAnimalsDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLMice, KnockoutMice, Transgenicalpha-SynucleinRab27b protein, mouserab GTP-Binding ProteinsA53T alpha-synuclein mutationAlpha-synucleinDementia with lewy bodiesParkinson’s diseaseRab27b

Identifiers

PMID42121002
PMCPMC13339369

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.